ResMed (RMD) PT Raised to $345 at UBS
Tweet Send to a Friend
UBS analyst Marcus Curley raised the price target on ResMed (NYSE: RMD) to $345.00 (from $335.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
